system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
the disclosing Party and Harpoon shall be deemed to be the receiving Party with respect thereto. In addition, all information disclosed by Harpoon to AbbVie under the Prior NDA shall be deemed to be Harpoon's Confidential Information disclosed hereunder, and all information disclosed by AbbVie Inc. to Harpoon under the Prior NDA shall be deemed to be AbbVie's Confidential Information disclosed hereunder. - 5 - Source: HARPOON THERAPEUTICS, INC., 10-K, 3/12/2020 1.43 "Control" means, with respect to any item of Information, Regulatory Documentation, material, Patent, or other property right, the possession of the right, whether directly or indirectly, and whether by ownership, license or otherwise (other than by operation of the license and other grants in Sections 5.1 or 5.2), to grant a license, sublicense or other right (including the right to reference Regulatory Documentation) to or under such Information, Regulatory Documentation, material, Patent, or other property right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party. "Controlled" has a corresponding meaning. 1.44 "CSR Notification Date" has the meaning set forth in Section 12.6.3(e). 1.45 "Default Notice" has the meaning set forth in Section 12.2.1. 1.46 "Delivery System" has the meaning set forth in the definition of "Net Sales." 1.47 "Development" means all activities related to pre-clinical and other non-clinical testing, test method development and stability testing, toxicology, formulation, process development, manufacturing scale-up, qualification and validation, quality assurance/quality control, Clinical Studies, including Manufacturing in support thereof, statistical analysis and report writing, the preparation and submission of Drug Approval Applications, regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required by a Regulatory Authority as a condition or in support of obtaining or maintaining a Regulatory Approval. When used as a verb, "Develop" means to engage in Development. For purposes of clarity, Development shall include any submissions and activities required in support thereof, required by Applicable Laws or a Regulatory Authority as a condition or in support of obtaining a pricing or reimbursement approval for an approved Licensed Product. 1.48 "Development Report Review Deadline" means [***] following the initial delivery of any [***], as applicable. 1.49 "Dispute" has the meaning set forth in Section 13.7. 1.50 "Distributor" has the meaning set forth in Section 5.4. 1.51 "Divestiture" means, with respect to a Party, (a) the divestiture [***] through [***] or [***] with respect to [***] (for clarity, the [***] for any such divestiture), or (b) [***]. When used as a verb, "Divest" and "Divested" means to cause a Divestiture. 1.52 "Dollars" or "$" means United States Dollars. 1.53 "Drug Approval Application" means a Biologics License Application (a "BLA") as defined in the PHSA, or any corresponding foreign application in the Territory, including, with respect to the European Union, a Marketing Authorization Application (a "MAA") filed with the EMA or with the applicable Regulatory Authority of a country in Europe with respect to the mutual recognition or any other national approval procedure. - 6 - Source: HARPOON THERAPEUTICS, INC., 10-K, 3/12/2020 1.54 "[***]" means the [***] by Harpoon to AbbVie within [***] following Harpoon's receipt of written notice from AbbVie pursuant to [***] prior to the date of AbbVie's receipt of the [***]. 1.55 "Effective Date" means the effective date of this Agreement as set forth in the preamble hereto. 1.56 "EMA" means the European Medicines Agency and any successor agency(ies) or authority having substantially the same function. 1.57 "European Major Market" means each of [***]. 1.58 "European Union" or "E.U." means the economic, scientific, and political organization of member states known as the European Union, as its membership may be altered from time to time, and any successor thereto. 1.59 "Existing Patents" has the meaning set forth in Section 10.2.1. 1.60 "Exploit," "Exploited" or "Exploitation" means to make, have made, import, export, use, sell, or offer for sale, including to Develop, Commercialize, register, modify, enhance, improve, Manufacture, have Manufactured, hold, or keep (whether for disposal or otherwise), formulate, optimize, have used, export, transport, distribute, promote, market, have sold or otherwise dispose of. 1.61 "FDA" means the United States Food and Drug Administration and any successor agency(ies) or authority having substantially the same function. 1.62 "FFDCA" means the United States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions, and modifications thereto). 1.63 "Field" means all human and non-human diagnostic,
"""

Extract the exact clause related to "Governing Law" from the excerpt above.